Stable amorphous form of a competitive potassium acid blocker and process for its preparation.

Description

1 / 16 “STABLE AMORPHOUS FORM OF A COMPETITIVE POTASSIUM ACID BLOCKER AND PROCESS FOR PREPARING THE SAME” Field of Invention

[001] The present invention relates to a stable amorphous Tegoprazan of formula (I).

[002] The present invention relates to a stable amorphous Tegoprazan, free from other forms in the solid state and stable throughout its shelf life, not converting into any other form in the solid state.

[003] The present invention also relates to a process for the preparation of stable amorphous Tegoprazan of formula (I).

[004] The present invention also relates to pharmaceutical compositions comprising the stable amorphous form of Tegoprazan. Background of the Invention

[005] Tegoprazan, a reversible H+ / K+-ATPase inhibitor, is chemically described as (S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo(d)imidazole-6-carboxamide. Its molecular formula is C20H19F2N3O3, its molecular weight is 387.38 g / mol, and its structure is as follows:

[006] Tegoprazan, the world's first competitive potassium acid blocker (P-CAB), has a mechanism similar to that of an acid pump antagonist (APA) and blocks gastric acid secretion by competing with ions of Petition 870260079713, dated 07 / 08 / 2026, p. 25 / 43 2 / 16 potassium by binding to the H+ / K+

[007] ATPase enzyme (proton pump) which secretes H+ ions, a component of gastric acid, from the gastric parietal cells into the gastric lumen. Because Tegoprazan is not a prodrug, like a proton pump inhibitor (PPI), it does not require an activation process and therefore acts not only on an active proton pump but also on an inactive proton pump. Thus, Tegoprazan has the advantages of exhibiting its effect rapidly and reaching its maximum effect within one hour.

[008] Polymorphism has been observed for Tegoprazan. US patent 9,908,870 B2 claims Form A of Tegoprazan with specific XRD data. This patent also describes non-crystalline Tegoprazan, prepared according to the method described in Example 2 of Japanese Patent No. 4481344. This patent describes solvent evaporation, carried out in a rotary evaporator under reduced pressure, with a bath temperature of up to 60 °C, resulting in a non-crystalline material. Another method described is purification by column chromatography on an amino acid gel (ethyl acetate:methanol gradient elution from 50:1 to 20:1) to provide the compound as a white solid.

[009] US patent 9,908,870 B2 also provides the stability of the non-crystalline form and Form A, as shown below: Table 1 Crystalline form Non-crystalline form Crystalline form A Period Initial stage After 4 weeks Initial stage After 4 weeks Appearance White powder Yellow powder White powder White powder Optical isomer content 0.04% 0.47% NDND Impurity content 0.16% 0.49% 0.10 0.10

[010] However, neither JP '344 nor US '870 provide the physicochemical characteristics of the non-crystalline material, nor the polymorphic purity and stability. Petition 870260079713, dated 07 / 08 / 2026, page 26 / 43 3 / 16 over the lifetime.

[011] It is known that the amorphous forms in various drugs exhibit different dissolution characteristics and, in some cases, different bioavailability patterns compared to the crystalline form (Econno T., Chem. Pharm. Bull., 1990; 38: 2003-2007).

[012] The amorphous form of some drugs exhibits much greater bioavailability than the crystalline forms, which leads to the selection of the amorphous form as the final drug substance for pharmaceutical dosage from development onwards. In addition, the aqueous solubility of the crystalline form is lower than that of the amorphous form in some drugs, which may have resulted in the difference in their bioavailability in vivo. Therefore, it is desirable to have stable amorphous Tegoprazan with high purity and good stability.

[013] Surprisingly, the inventors of the present invention have found that the stable amorphous Tegoprazan prepared according to the present invention exhibits high chemical purity, chiral purity, polymorphic purity and stability. OBJECTIVE OF THE INVENTION

[014] The main objective of the present invention is to provide stable amorphous Tegoprazan of formula (I).

[015] Another objective of the present invention is to provide stable amorphous Tegoprazan, free from other solid-state forms and stable throughout its shelf life, not converting into any other solid-state form.

[016] Another objective of the present invention is to provide a process for the preparation of stable amorphous Tegoprazan of formula (I).

[017] Another objective of the present invention is to provide pharmaceutical compositions comprising the stable amorphous form of Tegoprazan. SUMMARY OF THE INVENTION Petition 870260079713, dated 07 / 08 / 2026, p. 27 / 43 4 / 16

[018] Consequently, the present invention relates to a stable amorphous Tegoprazan of formula (I). ch3—ch3n Formula (I)

[019] The present invention also relates to a process for the preparation of stable amorphous Tegoprazan comprising the steps: i. provide a solution of Tegoprazan in a suitable solvent, ii. optionally treat the solution obtained in step (i) with charcoal, and iii. spray dry the resulting solution to obtain stable amorphous Tegoprazan.

[020] In another aspect, the present invention relates to a process for the preparation of stable amorphous Tegoprazan comprising the steps: I. prepare Tegoprazan by deprotecting the compound of formula (II) F Formula (II) whereby the amino Pg protecting group is obtained using a base in a solvent, ii) the obtained Tegoprazan is dissolved in a suitable solvent, ii) optionally the solution obtained in step (ii) is treated with charcoal, and Petition 870260079713, dated 07 / 08 / 2026, p. 28 / 43 5 / 16 iii) Dry the resulting solution by spraying to obtain stable amorphous Tegoprazan.

[021] In another aspect, the present invention relates to a process for the preparation of stable amorphous Tegoprazan comprising the steps: I. prepare Tegoprazan by detosylation of (-)-4-[((4S)-5,7-difluoro-3,4dihydro-2H-chromen-4-yl)oxy]-N,N,2-trimethyl-1-[(4-methylphenyl)-sulfonyl]-1H-benzimidazol-6carboxamide of formula (IIa) Formula (lia) with sodium hydroxide in a mixture of DMF and methanol, ii) dissolve the Tegoprazan obtained in a suitable solvent, ii) optionally treat the solution obtained in step (ii) with charcoal, and iii) spray dry the resulting solution to obtain stable amorphous Tegoprazan.

[022] In yet another aspect, the present invention relates to a process for the preparation of stable amorphous Tegoprazan comprising the steps: I. Prepare Tegoprazan by debenzylation of (S)-1-benzyl-4-((5,7-difluoro chroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[D]imidazole-6-carboxamide of formula (lib) Petition 870260079713, dated 07 / 08 / 2026, page 29 / 43 6 / 16 Formula (lib) Using a catalyst in a solvent, ii) dissolve the obtained Tegoprazan in a suitable solvent, ii) optionally treat the solution obtained in step (ii) with charcoal, and iii) spray dry the resulting solution to obtain stable amorphous Tegoprazan. Brief Description of the Drawings

[023] Figure 1: Represents the X-ray diffraction pattern of the stable amorphous Tegoprazan powder of the present invention.

[024] Figure 2: Represents the stable amorphous Tegoprazan DSC pattern of the present invention.

[025] Figure 3: Represents the stable amorphous Tegoprazan TGA of the present invention.

[026] Figure 4: Represents the X-ray diffraction pattern of stable amorphous Tegoprazan powder obtained by the spray drying process after 1 month of stability.

[027] Figure 5: Represents the X-ray diffraction pattern of stable amorphous Tegoprazan powder obtained by the spray drying process after 3 months of stability. Petition 870260079713, dated 07 / 08 / 2026, pages 30 / 43 7 / 16

[028] Figure 6: Represents the X-ray diffraction pattern of amorphous Tegoprazan powder obtained by rotary evaporation after 3 months of stability. Detailed Description of the Invention

[029] The present invention relates to stable amorphous Tegoprazan.

[030] In one aspect, the present invention provides stable amorphous Tegoprazan characterized by XRD, as shown in Figure 1.

[031] In one aspect, the present invention provides stable amorphous tegoprazan characterized by DSC, as shown in Figure 2. The stable amorphous tegoprazan melts with decomposition between 40 and 120 °C and does not exhibit a steep melting point.

[032] In one aspect, the present invention provides stable amorphous Tegoprazan characterized by TGA, as shown in Figure 3. The stable amorphous Tegoprazan of the present invention has a water content below 3.0%. Specifically, the product has a water content measured by thermogravimetry of 2.48 and by KF of 2.7 to 2.9, which remained unchanged throughout its shelf life.

[033] In another embodiment, the Tegoprazan starting material used in the present invention can be prepared by any of the procedures described in the prior art.

[034] The amino pg protecting group, as used herein, is benzyl, tosyl, t-butyloxycarbonyl and carboxybenzyl.

[035] The catalyst used here for the removal of the protecting group by hydrogenolysis uses a transition metal catalyst selected from Pd / C in the presence or absence of ammonium formate.

[036] The base, as used in the present invention, is selected from inorganic bases, such as alkali metal hydroxides, such as sodium hydroxide, potassium hydroxide, lithium hydroxide; alkali metal carbonates, Petition 870260079713, dated 07 / 08 / 2026, pages 31 / 43 8 / 16 such as sodium carbonate, potassium carbonate, cesium carbonate and lithium carbonate; alkali metal bicarbonates, such as sodium bicarbonate and potassium bicarbonate; alkali metal alkoxides, such as sodium methoxide, potassium methoxide, tertiary sodium butoxide, tertiary potassium butoxide or mixtures thereof, or organic bases, such as triethylamine, N-methylmorpholine, N,N-diisopropylethylamine, di-n-propylamine, N-methylpyrrolidine, pyridine, 4-(N,N-dimethylamino)pyridine, morpholine, imidazole, 2-methylimidazole, 4-methylimidazole and the like.

[037] Solvents as defined in the present invention are selected from aqueous solvents or alcohols, such as methanol, ethanol, n-propanol, isopropanol, n-butanol and t-butanol and the like, or hydrocarbon solvents, such as benzene, toluene, xylene, heptane, hexane and cyclohexane and the like, or ketone solvents, such as acetone, ethyl methyl ketone, diethyl ketone, methyl tert-butyl ketone, isopropyl ketone and the like, or ester solvents, such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, sec-butyl acetate and the like, or nitrile solvents, such as acetonitrile, propionitrile, butyronitrile and isobutyronitrile and the like, or ether solvents, such as di-tert-butylether, dimethylether, diethylether, diisopropylether, 1,4-dioxane, methyl tert-butylether, ethyl tert-butyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran, 2-methoxyethanol and dimethoxyethane, or amide solvents such as formamide,DMF, DMAC, N-methyl-2-pyrrolidone, N-methylformamide, 2-pyrrolidone, 1-ethenyl-2-pyrrolidone, haloalkanes such as dichloromethane, 1,2-dichloroethane and chloroform, amine solvents selected from diethylenetriamine, ethylenediamine, morpholine, piperidine, pyridine, quinoline, tributylamine, diisopropylamine, acids such as formic acid, acetic acid, propionic acid and / or mixtures thereof.

[038] The amorphous Tegoprazan of the present invention is stable throughout its shelf life under different stability conditions, consistently reproducible and has Petition 870260079713, dated 07 / 08 / 2026, pages 32 / 43 9 / 16 good flow properties, being particularly suitable for bulk preparation and handling. The stable amorphous Tegoprazan of the present invention is also suitable for formulation in different pharmaceutical forms.

[039] The stability data of the amorphous Tegoprazan of the present invention are compared with the product obtained in a rotary evaporator. The water content increases after 3 months and crystalline peaks are observed in XRD, showing the conversion from the amorphous to the crystalline form, as shown below. Table 2 Test Product obtained by evaporator thorium Product obtained by spray drying Initial time 3 months Initial 3 months Water content by KFR 1.44 3.32 2.78 2.92 XRD Absence of crystalline Crystallinity observed Absence of crystalline Absence of crystalline

[040] The data above clearly show that the non-crystalline material obtained by the prior art process, specifically using a rotary evaporator, does not exhibit polymorphic stability. The water content changed from the initial time up to 3 months of shelf life.

[041] Similarly, the amorphous nature is not maintained throughout the shelf life. This can be visualized from the XRD shown in Figure 6. The XRD pattern shown displays visible and clear peaks related to the crystalline form. On the other hand, the XRD pattern of stable amorphous Tegoprazan obtained by the spray drying process does not show crystallinity after 1 or 3 months. The XRD data of stable amorphous Tegoprazan obtained by the spray drying process after 1 month and 3 months are shown in Figures 4 and 5, respectively. Petition 870260079713, dated 07 / 08 / 2026, pp. 33 / 43 10 / 16

[042] In pharmaceutical products, both thermal stability and polymorphic stability are very important. Otherwise, one solid-state form converts into another solid-state form. Furthermore, there is no control over the conversion rate at different time intervals and under different storage conditions. This means that at different points in the shelf life, the product may exhibit a mixture of two different solid states in different proportions. It is clearly reported in the literature that this impacts the solubility and bioavailability of the product. This has a direct impact on the product's efficacy. Therefore, having polymorphic stability is very important.

[043] The stable amorphous Tegoprazan prepared by the process of the present invention is thermally stable when compared to the non-crystalline form obtained by the prior art process. The impurity profile data for both products are presented below: Table 3 Crystalline form Product obtained rotates by thorium evaporator Amorphous stable Tegoprazan Period Initial stage After 4 weeks Initial stage After 4 weeks Appearance White powder Yellow powder Beige powder Beige powder Optical isomer content 0.04% 0.47% ND / BDL ND / BDL Impurity content 0.16% 0.49% 0.09% 0.16% ND - Not detected; BDL - Below detection limits

[044] In a preferred embodiment, the present invention provides a stable amorphous tegoprazan pharmaceutical composition together with Petition 870260079713, dated 07 / 08 / 2026, pages 34 / 43 11 / 16 pharmaceutically acceptable excipients, such as diluents, chelating agents, disintegrants, glidants, lubricants and / or anti-adherents.

[045] The term pharmaceutical composition is intended to encompass a medicament including the active ingredient(s), pharmaceutically acceptable excipients that make up the vehicle, as well as any product that results, directly or indirectly, from the combination, complexation or aggregation of any two or more of the ingredients. Consequently, pharmaceutical compositions encompass any composition made by mixing the active ingredient, dispersion or composite of the active ingredient, additional active ingredient(s) and pharmaceutically acceptable excipients.

[046] Pharmaceutical compositions comprising stable amorphous Tegoprazan may be further formulated as: solid oral dosage forms, such as, but not limited to, powders, granules, pellets, tablets and capsules; liquid oral dosage forms, such as, but not limited to, syrups, suspensions, dispersions and emulsions; and injectable preparations, such as, but not limited to, solutions, dispersions and lyophilized compositions. The formulations may be in the form of immediate-release, delayed-release or modified-release. In addition, immediate-release compositions may be conventional, dispersible, chewable, buccal-dissolving or instant-melting preparations, and modified-release compositions may comprise hydrophilic or hydrophobic substances, or combinations of hydrophilic and hydrophobic substances, which control the release rate to form a matrix or reservoir or a combination of matrix and reservoir systems.The compositions can be prepared using procedures such as direct mixing, dry granulation, wet granulation, or extrusion and spheronization. The compositions can be presented as uncoated, film-coated, sugar-coated, powder-coated, enteric-coated, or modified-release coated. Petition 870260079713, dated 07 / 08 / 2026, pages 35 / 43 12 / 16 compositions of the present application may also include one or more pharmaceutically acceptable excipients.

[047] The present invention is further illustrated by the following examples, which are provided merely as examples of the invention and are not intended to limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and should be included within the scope of the present invention. EXAMPLES

[048] Example 1 - Process for the preparation of stable amorphous Tegoprazan

[049] To a stirred solution of (S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1-tosyl-1H-benzo[d]imidazole-6-carboxamide (Tegoprazan Step 1) (30.0 g, 55 mmoles), in 270 mL of isopropyl alcohol, sodium hydroxide solution (12 g, 300 mmoles dissolved in 150 mL of water) at 25-30 °C was added and the resulting solution was stirred for 4.0-5.0 hours at 25-30 °C. The progress of the reaction was monitored by TLC (mobile phase: chloroform: methanol in the ratio of 9.2:0.8). The reaction mass was diluted with 300 mL of ethyl acetate and separated, the aqueous layer was extracted with 75 mL of ethyl acetate. The combined organic layer was washed with 3 x 300 mL of demineralized water.The resulting organic layer was diluted with 150 mL of demineralized water, the pH was adjusted to 2.0-3.0 with aqueous HCl at 10-15 °C, maintained for 10-20 min at 10-15 °C, and the pH of the reaction mass was readjusted to 7.0-8.0 with ammonia solution. The organic layer was separated, followed by washing with demineralized water and drying over sodium sulfate. Finally, it was distilled under vacuum below 55 °C to obtain crude material, which was isolated in 60 mL of methyl ethyl ketone at 0-5 °C. Finally, this material was purified in 45 mL of isopropyl alcohol to obtain wet material. This wet material was dissolved in methanol, treated with activated carbon, and fed into... Petition 870260079713, dated 07 / 08 / 2026, pages 36 / 43 13 / 16 spray dryer according to the conditions mentioned below to obtain the wet material. 1. Feeding rate: 15-20 mL / min 2. Inlet temperature: 45-50°C. 3. Output temperature: 25-30°C. 4. Atomizer pressure: 1±0.5 kg / cm2. 5. % oxygen: NMT 5.0%

[050] The wet material obtained above was dried for 12 to 14 hours under vacuum at 55-60°C to obtain the amorphous form of (S)-7-((5,7-difluorochroman-4-yl)-oxy)-N,N,2-trimethyl-1H-benzo[D]imidazole-5-carboxamide (Tegoprazan Amorphous) (molar yield of 66% with purity above 99.5%).

[051] Example 2 - Process for the preparation of stable amorphous Tegoprazan

[052] The process involves the debenzylation of 100 g of (S)-1-benzyl-4-((5,7difluorochroman-4-yl)-oxy)-N,N,2-trimethyl-1H-benzo[D]imidazole-6-carboxamide with 15 g of Pd / C in 10 V of methanol. The reaction mass was filtered and the solvent medium was completely distilled after completion of the TLC. To the reaction mass, 2.5 V of MTBE was added and heated to 70-75 °C for 1 h. The reaction mass was cooled and the solid was filtered. The solid was subsequently crystallized in IPA to obtain (3R,4S)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide via wet processing. The resulting wet material was dissolved in methanol (10 volumes), followed by treatment with activated charcoal, and after spray drying, a clear solution was observed. Tegoprazan, amorphous form (molar yield of 65% with purity above 99.5%).

[053] Example 3 - Process for the preparation of stable amorphous Tegoprazan

[054] The process involves the debenzylation of 100 g of (S)-1-benzyl-4-((5,7Petition 870260079713, dated 07 / 08 / 2026, page 37 / 43 14 / 16 difluorocroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[D]imidazol-6-carboxamide with 15 g of Pd / C in 10 V of methanol. The reaction mass is filtered and the solvent medium is completely distilled after completion of the TLC. To the reaction mass, 2.5 V of MTBE was added and it was heated to 70-75 °C for 1 h. The reaction mass was cooled and the solid was filtered. The solid was subsequently crystallized in IPA to obtain (3R,4S)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide by wet process. The wet material obtained was dissolved in ethanol (20 volumes) followed by treatment with charcoal to obtain a clear solution after spray drying. The results were: Tegoprazan in amorphous form (molar yield of 60% with purity above 99.5%).

[055] Example 4 - Process for preparing stable amorphous Tegoprazan

[056] The process involves the debenzylation of 100 g of (S)-1-benzyl-4-((5,7difluoro chroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[D]imidazole-6-carboxamide with 15 g of Pd / C in 10 V of methanol. The reaction mass is filtered and the solvent medium is completely distilled after the completion of the TLC. To the reaction mass, 2.5 V of MTBE was added and heated to 70-75 °C for 1 h. The reaction mass was cooled and the solid was filtered. The solid was subsequently crystallized in IPA to obtain (3R,4S)3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide via wet processing. The resulting wet material was dissolved in IPA (50 volumes), followed by charcoal treatment, to obtain a clear solution after spray drying. Tegoprazan is presented in amorphous form (70% molar yield with purity above 99.5%).

[057] Example 5 - Process for preparing stable amorphous Tegoprazan Petition 870260079713, dated 07 / 08 / 2026, pp. 38 / 43 15 / 16

[058] The process involves the debenzylation of 100 g of (S)-1-benzyl-4-((5,7difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[D]imidazole-6-carboxamide with 15 g of Pd / C in 10 V of methanol. The reaction mass is filtered and the solvent medium is completely distilled after completion of the TLC. To the reaction mass, 2.5 V of MTBE was added and heated to 70-75 °C for 1 h. The reaction mass was cooled and the solid was filtered. The solid was subsequently crystallized in IPA to obtain wet (3R,4S)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide. The wet material obtained was dissolved in n-butanol (20 volumes), followed by treatment with charcoal, and a clear solution was obtained after spray drying. The result was the amorphous form of Tegoprazan (molar yield of 64% with purity above 99.5%).

[059] Example 6 - Process for the preparation of stable amorphous Tegoprazan

[060] The process involves the debenzylation of 100 g of (S)-1-benzyl-4-((5,7difluoro chroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[D]imidazole-6-carboxamide with 15 g of Pd / C in 10 V of methanol. The reaction mass is filtered and the solvent medium is completely distilled after completion of the TLC. To the reaction mass, 2.5 V of MTBE was added and heated to 70-75 °C for 1 h. The reaction mass was cooled and the solid was filtered. The solid was subsequently crystallized in IPA to obtain wet (3R,4S)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide. The wet material obtained was dissolved in DCM (10 volumes), followed by charcoal treatment, and the clear solution obtained after spray drying resulted in the amorphous form of Tegoprazan (molar yield of 67% with purity above 99.5%).

[061] Comparative Example - Process for the preparation of Tegoprazan by Rotary Evaporator Petition 870260079713, dated 07 / 08 / 2026, pp. 39 / 43 16 / 16

[062] The wet material obtained in Example 1 or 2 was dissolved in methanol, followed by charcoal treatment, and the clear solution obtained was subjected to a rotary evaporator and distilled completely in methanol under vacuum (650+50 mm / Hg) at a temperature below 55°C. Degass for 30 to 40 minutes under vacuum (650 + 50 mm / Hg) at temperatures below 55°C and scrape the material to make it into powder. Continue degassing for 2.0 to 3.0 minutes under vacuum (650 + 50 mm / Hg) at temperatures below 55°C. Dry the material for 12 to 14 hours at temperatures of 55 to 60°C under vacuum. Tegoprazan: amorphous form (molar yield of 60% with purity above 99.5%). Petition 870260079713, dated 07 / 08 / 2026, pp. 40 / 43

Claims

1 / 3 CLAIMS 1. Stable amorphous tegoprazan, CHARACTERIZED in that it has the formula (I) 2. Stable amorphous tegoprazan, according to claim 1, CHARACTERIZED in that XRD as shown in Figure 1, DSC as shown in Figure 2 and melting with decomposition between 40 and 120 °C.

3. Stable amorphous tegoprazan, according to claim 1, CHARACTERIZED in that it has a water content below 3.0%.

4. Process for the preparation of stable amorphous Tegoprazan, according to claim 1, CHARACTERIZED in that it comprises the steps: i) providing a solution of Tegoprazan in a suitable solvent, ii) optionally treating the solution obtained in step (i) with charcoal, and iii) spray-drying the resulting solution to obtain stable amorphous Tegoprazan.

5. Process for the preparation of stable amorphous Tegoprazan, according to claim 1, CHARACTERIZED in that it comprises the steps: i) preparing Tegoprazan by deprotecting the compound of formula (II) Petition 870260079713, dated 07 / 08 / 2026, page 41 / 43 2 / 3 Formula (II) in which Pg amino protecting group using a base in a solvent, ii) dissolving the Tegoprazan obtained in a suitable solvent, ii) optionally treating the solution obtained in step (ii) with charcoal, and iii) spray drying the resulting solution to obtain stable amorphous Tegoprazan.

6. Process, according to claim 5, CHARACTERIZED in that Pg is benzyl, tosyl, t-butyloxycarbonyl and carboxybenzyl.

7. Process, according to claim 5, CHARACTERIZED in that Pg is deprotected by hydrogenolysis using a transition metal catalyst selected from Pd / C in the presence or absence of ammonium formate.

8. Process, according to claim 5, CHARACTERIZED in that the base is sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium methoxide, tertiary sodium butoxide, tertiary potassium butoxide, triethylamine, N-methylmorpholine, N,N-diisopropylethylamine, di-n-propylamine, N-methylpyrrolidine, pyridine, 4-(N,N-dimethylamino)pyridine, morpholine, imidazole, 2-methylimidazole, 4-methylimidazole. Petition 870260079713, dated 07 / 08 / 2026, pp. 42 / 43 3 / 3 9. Process according to claim 5, CHARACTERIZED in that the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, benzene, toluene, xylene, heptane, hexane, cyclohexane, acetone, ethyl methyl ketone, diethyl ketone, methyl tert-butyl ketone, isopropyl ketone, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, sec-butyl acetate, acetonitrile, propionitrile, butyronitrile and isobutyronitrile di-tert-butyl ether, dimethyl ether, diethyl ether, diisopropyl ether, 1,4-dioxane, methyl tert-butyl ether, ethyl tert-butyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, 2-methoxyethanol and dimethoxyethane, formamide, DMF, DMAC, N-methyl-2-pyrrolidone, N-methylformamide, 2-pyrrolidone, 1-ethenyl-2-pyrrolidone, dichloromethane, 1,2-dichloroethane, chloroform, diethylenetriamine, ethylenediamine, morpholine, piperidine, pyridine, quinoline, tributylamine, diisopropylamine, formic acid, acetic acid,Propionic acid and / or mixtures thereof. Petition 870260079713, dated 07 / 08 / 2026, page 43 / 43.

Images